secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001193125-24-002892
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Therapeutics prices $300M public offering of 17.15M shares at $17.50/share
-------------------------------------------------------------------------------

- Gross proceeds ~$300.1M from 17,150,000 shares; net proceeds ~$281.6M after discounts and expenses.
- Underwriters have 30-day option for up to 2,572,500 additional shares; if exercised, net ~$323.9M.
- Proceeds plus existing cash expected to fund operations through 2025.
- Offering led by Morgan Stanley, J.P. Morgan, Jefferies, Stifel; expected to close January 9, 2024.
- Shares sold by Dyne; no selling stockholders participating.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000119312524002892/0001193125-24-002892-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000119312524002892/d110504d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-002892

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer